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Abstract 
The study examines the impact of corporate governance on the performance of the 
pharmaceutical industry in Pakistan. Secondary data obtained from annual reports of 
the respective pharmaceutical companies. One hundred and ten national and 
multinational Pharmaceutical firms were selected through convenient sampling method 
over the period of 2003 to 2013 (total observations = 1210). The panel data approach 
was used by employing correlation test, Fixed Effects Model (FEM), Random Effects 
Model (REM), multicollinearity test, and hausman test. The hausman test was used to 
differentiate between FEM and REM in panel data. The p-value in hausman test is 
significant (chi2 (9) = 61.940, prob > chi2 = 0.000), therefore, fixed effect model was 
used to examine the relationship between corporate governance and financial 
performance. The results of this study revealed that the relationship among CEO 
duality, board size, board committees, board compensation, board education, board 
experience, board diversity and board independent director and return on assets were 
found positive. Moreover, the relationship between board composition and return on 
assets were observed negative. Overall, it was concluded that corporate governance 
positively impacted the performance of national and multinational pharmaceutical firms 
in Pakistan.  
Key Words: Corporate Governance, Financial Performance, Return on Assets 
and Pharmaceutical Sector 
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Introduction  
The corporate governance (CG) has become an attractive debatable topic after 
happening renowned global financial scandal such as WorldCom, Enron, Tyco, 
Andersen, Swiss Air, Kirch Media and Daiwa Bank. Therefore, the need for corporate 
governance has been recognized both in developed and developing economies. The 
empirical studies of Chugh et al. (2011) and Rezaee (2008) found that best practices of 
corporate governance enhance performance of a firm. Moreover, practices of corporate 
governance boost financial and operational performance of a firm. Hence, optimal 
allocation of resources and better governance is the benchmark for the success of the 
firm. In this way, the performance of the firms would be the focal point for 
shareholders, creditors, employees, customers, and the economy at large. Therefore, it 
is vital that Pakistani industrial sector to implement best practices of corporate 
governance, in order to achieve economic development. The objective of the study is to 
establish the association between corporate governance and financial performance of 
Pharmaceutical Companies in Pakistan. Hence, generally, this study examines the 
impact of corporate governance (CG) on the financial performance of Pharmaceutical 
Companies in Pakistan. 
Literature Review 
Studies by Fama and Jensen (1983), exhibited that the incentive for non-
executive directors were more to protect the shareholder interest. Wanyama and 
Olweny (2013) explored positive relationship between board composition and financial 
performance of the insurance companies. Garba et al. (2014) found a negative 
relationship between board composition and financial performance. Bonsa (2015) 
revealed a negative relationship between board size and corporate   performance. 
Ongore et al. (2014) showed a negative relationship between board size and financial 
performance. Yemane et al. (2015) revealed a negative relationship between board size 
and performance of the Ethiopian insurance companies. Arslan et al. (2014) 
documented that there was a positive relationship between audit committee and 
corporate performance. Shareholders of the firm trust on boards when there were 
identified committees. Wahba (2015) concluded that CEO duality negatively affect the 
financial performance. Faleye (2007), showed that duality of the CEO was positively 
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associated to CEO reputation, managerial ownership and organizational complexity. 
Dahya and Travlos (2000), reported a positive relationship between duality of the CEO 
and firm endogeneity of selection of leadership. Yemane et al. (2015) found a positive 
significant relationship between board compensation and firm performance. Bonsa 
(2015) argued board education and board experience was positively associated with the 
financial performance of the firms. Poon, Heong and Lee, (2013) found that there was a 
positive relationship between board education and corporate performance.  According 
to Kroll, et al. (2008) board with more relevant experience was associated with higher 
return. The idea of an independent director is of vital importance in the field of 
corporate   governance. Ongore et al. (2015) found a negative association between 
board independence and financial performance. Based on the argument provided by 
Bhagat and Black (2001), that there were negative associations between board 
independence and firm performance. The gender and minority questions in corporate 
governance have generated debate in recent years. Ongore et al. (2014) revealed a 
positive relationship between board diversity and financial performance.  
Research Methodology 
3.1  Population and Sample Size  
The population of the study consists of multinational as well as national pharmaceutical 
companies operated in Pakistan. In this study, the convenient sampling method was 
used, where the annual reports availability of the selected firms plays an important role 
in the inclusion of the final list. One hundred and ten national and multinational 
pharmaceutical firms were selected over the period of 2003 to 2013 (total observations 
= 1210).  The annual reports of the multinational pharmaceutical firms were taken from 
the website of the State Bank of Pakistan and Karachi Stock Exchange, whereas the 
annual reports of the national pharmaceutical firms were mostly obtained on manual 
way.   
3.2 Methods of Analysis and Research Model 
The panel data approach was used in this study as it has some advantages over time 
series and cross sectional regression. Panel data easily detect that simply cannot be 
observed in pure time series and pure cross-section data (Gujarati, 2003).  
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The specifications of the model are as follows: 
Econometric Model  
yIt =  β0+ βFit+ εit ............................................................................................ (1) 
In the above model (1), Y shows dependent variable (return on asset). β0 
represents the coefficient,  Fit  denotes independent variables and εit shows error term.  
ROAIt = f (BCOMP, BSIZE, BCOMMITTES, CEODUALITY, BCOMPENSATION, 
BEDU, BEXP,BINDP, BDIVERSITY)........................................................................(2) 
ROAIt = β0+ β1 BCOMP it+ β2BSIZEit+ β3 BCOMMITTES it+ β4 CEODUALITY it         
β5 BCOMPENSATION it+ β6 BEDU it+ β7BEXPit+ β8BINDPit+ β9BDIVERSITYit+ 
εiit..................................................................................................................................(3) 
Where; 
ROA   =Return on Assets i at period t 
 
BCOMP 
BSIZE                                                  
=Board Composition 
= Board Size 
BCOMMITTES = Board Committees 
CEODUALITY =Duality of the Chief Executive Officer   
BCOMPENSATION =Board Compensation 
BEDU =Board Education 
BEXP =Board Experience 
BINDP =Board Independent Director 
BDIVERSITY =Board Diversity 
i = 1 to 110 Firms 
t = 2003----2013 
u it = Error Term. 
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Figure 1: Conceptual Framework 
 
 
 
3.4 Hypotheses  
As the objective of the study was to examine the relationship between corporate 
governance and financial performance of pharmaceutical companies in Pakistan. In 
order to achieve this objective, various hypotheses have been constructed. Hypothesis 
are developed to find out the impacts of corporate governance (board composition, 
board size, board committees, CEO duality, board compensation, board education, 
board experience, independent directors and board diversity) extracted from the 
literature on the dependant variable measured by ROA. Therefore, current study 
developed the following hypotheses: 
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H1a: There is significant positive relationship between board composition and 
performance of the pharmaceutical companies in Pakistan.  
 
 
Board Size: 
H1b: There is significant positive relationship between board size and performance of 
the pharmaceutical companies in Pakistan.  
Board Committees: 
H1c: There is significant positive relationship between board committees and 
performance of the pharmaceutical companies in Pakistan.  
Duality of the CEO: 
H1d: There is significant positive relationship between CEO duality and performance of 
the pharmaceutical companies in Pakistan. .  
Board Compensation: 
H1e: There is significant positive relationship between board compensation and 
performance of the pharmaceutical companies in Pakistan.  
Board Education: 
H1f: There is significant positive relationship between board education and performance 
of the pharmaceutical companies in Pakistan.  
Board Experience: 
H1g: There is significant positive relationship between board experience and 
performance of the pharmaceutical companies in Pakistan.  
Independent Directors:  
H1h: There is significant positive relationship between independent directors and 
performance of the pharmaceutical companies in Pakistan.  
Board Diversity: 
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H1i: There is significant positive relationship between board diversity and performance 
of the pharmaceutical companies in Pakistan. 
 
 
 
Results and Discussions 
As given in Table 1, the results of the study are calculated using statistical and 
mathematical tools with the help of SPSS software version IBM 20. The correlation 
among variables are calculated at first step to establish the relationship between 
dependent and independent variables. Moreover, multicollinearity problem among 
explanatory variables is also addressed in the study as shown in Table 2.  
Table 1 depicts correlation matrix of return on assets (predictor variables) and 
explanatory variables. The explanatory variables in this study are board composition, 
size of board, board committees, CEO duality, board compensation, board education, 
board experience, independent director and board diversity. As shown in table 1, there 
was a negative relationship between board composition and return on assets. This 
relationship revealed an inverse association between board composition and return on 
assets.
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Table 1  
Correlation Matrix (Corporate Governance and ROA) 
Variables* ROA 
Board 
Composition 
Board 
Size 
Board 
Committees 
CEO 
Duality 
Board 
Compensation 
Board 
Education 
Board 
Experience 
Independe
nt Director 
Board 
Diversity 
ROA 1.000          
Board 
Composition 
-0.420 1.000         
Board Size 0.380 0.400 1.000        
Board 
Committees 
0.610 0.220 0.080 1.000       
CEO Duality 0.510 0.180 0.250 0.080 1.000      
Board 
Compensation  
0.490 0.090 0.220 0.170 0.390 1.000     
Board Education  0.730 0.110 0.370 0.120 0.270 0.360 1.000    
Board Experience  0.330 0.160 0.460 0.190 0.240 0.150 0.230 1.000   
Independent 
Director 
0.640 0.210 0.300 0.270 0.200 0.070 0.120 0.320 1.000  
Board Diversity 0.510 0.340 0.270 0.340 0.060 0.250 0.190 0.260 0.340 1.000 
Source: Output from Data of Sampled Pharmaceutical Companies 2003-2013 & Author calculation  
*Size of sample (n) = 1210 company year observations over the period of 2003–2013 based on the availability of company data.  
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Furthermore, a positive relationship was found between return on assets and 
board size. This positive association between size of the board and return on assets 
showed that board size positively affects the return on assets of the pharmaceutical 
firms. The results further exhibited that the association between board committees and 
return on assets was positive. This relationship illustrated the firms having board 
committees were achieving a positive return on their assets. In table 1, the analysis 
demonstrated that there was a positive relationship between CEO duality and return on 
assets. As can be seen in the above correlation table, there was a positive relationship 
between predictor variables (return on assets) and board compensation. The strong 
linear relationship was reported between board education and return on assets of the 
pharmaceutical firms in Pakistan. As presented in correlation table, there was a positive 
relationship between board experience and return on assets. As can be described in 
table 1, a moderate positive association was observed between independent director and 
return on assets. It can be seen from the table 1, the relationship between board 
diversity and return on assets was moderate. This relationship depicted that firms 
having diversity in their board received more return on their assets.  
 
Table 2  
Variance Inflation Factors  
S.No Variables Variance Inflation 
Factors (VIF) 
Tolerance Value 
(1/VIF) 
1 Board Composition 1.16 0.86207 
2 Board Size 1.22 0.81967 
3 Board Committees 1.41 0.70922 
4 CEO Duality 1.13 0.88495 
5 Board Compensation 1.09 0.91743 
6 Board Education 1.19 0.84033 
7 Board Experience 1.32 0.75757 
8 Independent Director 1.53 0.65359 
9 Board Diversity 1.29 0.77519 
Source: Output from Data of Sampled Pharmaceutical Companies 2003-2013 & Author calculation. 
 
 
Table 2 depicts variance inflation factors among independent variables of multinational 
firms. If the value of the variance inflation factors exceeded from 10, it indicates that 
the associated regression coefficients are not weakly estimated due to multicollinearity. 
As presented in table 2, Variance Inflation Factors (VIF) values of all independent 
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variables are less than 10, which indicated that there is no multicollinearity problem 
among explanatory variables. 
Table 3  
Hausman Test for Random and Fixed Effect Models 
 
H0: Random Effect Model Technique is 
Appropriate  
H1: Fixed Effect Model Technique is Appropriate 
Dependent Variable: ROA 
Method: Hausman Test 
Date: 02/06/2015 
Sample: 2003—2013 
Period Included: 13 
Cross Sections Included: 110 
Total Panel Observations: 1210 
Hausman Test for random and fixed effect 
models: 
 
Test Summary 
                chi2 (9) = 61.940 
                                   Prob >chi2 = 0.000 
 
Source: Output from Data of Sampled Pharmaceutical Companies 2003-2013 & Author calculation. 
 
Table 3 presents the summary of the Hausman specification test for random and fixed 
effect models. A most common practice in corporate governance study is to select 
between random and fixed effect models methods by running a Hausman specification 
test. Hausman test has been used in this study to make sure that whether the fixed effect 
model is more appropriate or random effect model for the study. If the P-value is 
insignificant, larger than 5 percent, then the random effect model is more suitable. 
However, if the P-value is significant, then fixed effect model is more appropriate. As 
is presented in table 3, the P-value is significant; therefore fixed effect model was used 
to examine the relationship between corporate governance and return on assets. Thus, 
alternate hypothesis is accepted.  
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Table 4 
 
Results of Fixed Effect Model  
            Observation Per Group:  
            Min. = 11.00            
            Max. =11.00 
            Avg. =11.00 
            Number of Groups:   110 
            R- Squared:  0.792 
            F- Statistic (9, 1190): 14.587 
            Prob>F:  0.000 
          Dependent Variable: ROA 
          Method: Fixed Effect Test 
          Date: 02/06/2015 
          Sample: 2003—2013 
          Period Included: 13  
          Cross Sections Included: 110 
          Total Panel Observations: 1210 
          Size of Sample (n=120***) 
Variables Hypotheses Coefficient     t-value Significant 
Level  
Comments   
Constant   -2.350167 -02.455** Significant 
at 0.050 
 
Board 
Composition 
HOa 
H1a 
-0.298765 -04.577** Significant 
at 0.050 
Null 
Hypothesis is 
Accepted 
Board Size HOb 
H1b 
0.357986 06.456* Significant 
at 0.010 
Alternative 
Hypothesis is 
Accepted 
Board 
Committees 
HOc 
H1c 
0.579865 12.567* Significant 
at 0.010 
Alternative 
Hypothesis is 
Accepted 
CEO Duality HOd 
H1d 
0.443689 25.654* Significant 
at 0.010 
Alternative 
Hypothesis is 
Accepted 
Board 
Compensation  
HOe 
H1e 
0.519754 08.345* Significant 
at 0.010 
Alternative 
Hypothesis is 
Accepted 
Board 
Education  
HOf 
H1f 
0.589645 10.653* Significant 
at 0.010 
Alternative 
Hypothesis is 
Accepted 
Board 
Experience  
HOg 
H1g 
0.627896 08.416* Significant 
at 0.010 
Alternative 
Hypothesis is 
Accepted 
Independent 
Director 
HOh 
H1h 
0.696246 18.932* Significant 
at 0.010 
Alternative 
Hypothesis is 
Accepted 
Board 
Diversity 
HOi 
H1i 
0.598532 22.326* Significant 
at 0.010 
Alternative 
Hypothesis is 
Accepted 
Source: Output from Data of Sampled Pharmaceutical Companies 2003-2013 & Author calculation         
* Significant at 0.99 level of confidence  
**Significant at 0.95 level of confidence  
***Size of sample (n) = 1210 company year observations over the period of 2003–2013 based on the 
availability of company data.  
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Table 4 illustrated the regression analysis of national and multinational pharmaceutical 
firms working in Pakistan. According to the data in the table 4, the overall model has 
been fitted. The R- square value (0.792) reveals that 79 percent deviation in return on 
assets is due to corporate governance variables used in this study.  
As is evident from the data in table 4, there was a negative relationship between board 
composition and return on assets (coefficient value of board composition is         -
0.298765, t-value of board composition is -04.577, and the result is significant at 
0.050). The study assigns one if the board of the pharmaceutical firms includes 
executive as well as non-executive directors, including independent directors and zero 
was assigned if the board does not include executive and non-executive directors 
including independent directors. This negative relationship indicated that the firms in 
which the board includes executive and non-executive directors, including independent 
directors received a negative return on their assets. Thus, the null hypothesis (HOa) is 
accepted, which states there is no significant positive relationship between board 
composition and performance of the pharmaceutical companies in Pakistan.  
In table 4, the analysis confirmed that board size was positively related with return on 
assets. The coefficient value of board size is 0.357986, t-value of board size is 06.456, 
its p-value smaller than 0.05 and the result is significant at 1 percent. It implied that the 
large board size of the firms has significant influenced on the performance of 
pharmaceutical firms in Pakistan. The finding supported the view that large size of the 
board is effective in controlling and monitoring company management and it help to 
decrease agency cost. Therefore, the alternative hypothesis (H1b) is accepted, which 
states that there is significant positive relationship between board size and performance 
of the pharmaceutical companies in Pakistan.  
As shown in table 4, board committees were statistically significant (p-value smaller 
than 0.01). This relationship revealed that board committees were positively linked 
with a return on assets. The study allocated zero if the firm have less than three 
committees (namely audit committee, the nomination committee and remuneration 
committee) and assigned one if the firms having all three committees. The firm, having 
all three committees are more able to convert their resource into a profit. Null 
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hypothesis (HOc) predicts that there is no significant positive relationship between 
board committees and performance of the pharmaceutical companies in Pakistan. The 
positive and significant coefficient of the board committees does not support this 
hypothesis. Thus, the alternative hypothesis (H1c) which states there is significant 
positive relationship between board committees and performance of the pharmaceutical 
companies in Pakistan is accepted. 
The results in table 4 demonstrated that CEO duality was significantly connected with a 
return on assets (the coefficient value of CEO duality is 0.443689, t-value of CEO 
duality is 25.654 and its p-value smaller than 0.01. This positive relationship exhibited 
that the firms in which the CEO and the chairperson position held by similar individual 
was capable to convert organizational resource more efficiently. Therefore, the 
alternative hypothesis (H1d) is accepted. The alternative hypothesis, which states there 
is significant positive relationship between CEO duality and performance of the 
pharmaceutical companies in Pakistan.  
Board compensation was positively related with return on assets (the t-value of board 
compensation is 08.345 and its p-value smaller than 0.01). This positive relationship 
described that directors on the board whose get handsome compensation were working 
more efficiently. Thus, alternative hypothesis (H1e) which states there is significant 
positive relationship between board compensation and performance of the 
pharmaceutical companies in Pakistan is accepted.   
As is evident from the data in table 4, board education was positively linked with a 
return on assets. The coefficient value of board education is 0.589645; t-value of board 
education is 10.653 and its p-value is smaller than 0.010. Hypothesis H1f predicts that 
there is significant positive relationship between board education and performance of 
the pharmaceutical companies in Pakistan. The positive and significant coefficient of the 
board education supports this hypothesis.  
It can be seen from the regression table that board experience was significantly linked 
with a return on assets. The coefficient value of board experience is 0.627896, t-value 
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of board experience is 08.416 and its p-value smaller than 0.01. This positive 
relationship exhibited that experienced board members were more able to get more 
return on firm assets. Thus, the alternative hypothesis (H1g) is accepted.   
Positive significant relationship was found between independent director and financial 
performance measured by ROA (the coefficient value of independent director is 
0.696246, t-value of independent director is 18.932 and its p-value smaller than 0.01. 
This positive relationship explained that firms having more an independent director on 
their board were competent to convert firm financial resource into a profit. The study 
rejected the null hypothesis (Hoi), which states that there is no significant positive 
relationship between independent directors and performance of the pharmaceutical 
companies in Pakistan. Therefore, the study accepted the alternative hypothesis (H1i). 
As is clear from table 4, board diversity was positively related with return on assets of 
the firm (the t-value of board diversity is 22.326 and its p-value smaller than 0.01). 
This significant relationship between board diversity and return on assets showed that 
firms having diversity on their board was more successful to receive more return on 
their assets. Hypothesis Hog predicts that there is no significant positive relationship 
between board diversity and performance of the pharmaceutical companies in Pakistan. 
The positive and significant coefficient of the board diversity does not support this 
hypothesis. Therefore, H1g is accepted, which states there is significant positive 
relationship between board diversity and performance of the pharmaceutical companies 
in Pakistan.  
Conclusion  
The Corporate Governance (CG) has received great attention among the policy makers, 
government officials, corporate managers, scholars, strategists, academician and public 
in recent years. The study examined the impact of corporate governance on assets 
return of the pharmaceutical industry in Pakistan. This study measured the dimensions 
of corporate governance in terms of board size, board committee, board diversity, board 
independent directors and the duality of the CEO.  The convenient sampling method 
was used, where the annual reports availability of the selected firms plays an important 
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role in the inclusion of the final list. One hundred and ten national and multinational 
pharmaceutical firms were selected over the period of 2003 to 2013 (total of 1210 
observations).  Hausman test was used in this study to check out that whether fixed 
effect model was more appropriate or random effect model for this study. Based on the 
results, it can be concluded that the relationship of board size, CEO duality, board 
committees, board compensation, board education, board independent director board 
experience, board diversity with return on assets were found positive.  On the other 
hand, the relationship of board composition with assets return was observed negative. 
Overall, it was concluded that good corporate governance positively affected the 
performance of national and multinational pharmaceutical firms in Pakistan. The study 
suggests best practices of corporate governance not only n manufacturing sector but 
also in service industry at corporate level to achieve competitive advantage in the 
global competition. Moreover, same study may be conducted in other industries to 
assess the overall economic impact due to governance.  
 
 
 
 
 
 
 
 
JULY-Dec 2017, VOL 3, ISSUE 2 JOURNAL OF MANAGEMENT RESEARCH (JMR) 
 
174 
References 
Arslan, M., Zaman, R., Malik, R. K. & Mehmood, A. (2014b). Impact of CEO Duality 
and Audit Committee on Firm Performance: A Study of Oil & Gas Listed Firms 
of Pakistan. Research Journal of Finance and Accounting, 5, 151-156. 
Bhagat, S., & Black, B. (2001). Non-Correlation between Board Independence and 
Long-Term Firm Performance, The. J. CorP. l., 27, 231.  
Bonsa, M. (2015). Impacts of Corporate Governance Mechanism on Financial 
Performance of Selected Insurers in Ethiopia (Doctoral dissertation, AAU). 
Chugh, L. C., Meador, J. W., & Kumar, A. S. (2011). Corporate governance and firm 
performance: evidence from India. Journal of finance and Accounting, 7, 1–10. 
Dahya, J., & Travlos, N. (2000). Does the one man show pay? Theory and evidence on 
the dual CEO revisited. European Financial Management, 6(1), 85-98.  
Faleye, O. (2007). Does one hat fit all? The case of corporate leadership structure. 
Journal of Management & Governance, 11(3), 239-259.  
Fama, E. F., & Jensen, M. C. (1983). Separation of ownership and control. Journal of 
law and economics, 301-325. 
Garba, T., Abubakar, B. A., Garba, T., & Abubakar, B. A. (2014). Corporate Board 
Diversity and Financial Performance of Insurance Companies in Nigeria: An 
Application of Panel Data Approach. Asian Economic and Financial Review, 
4(2), 257-277. 
Gujarati, D. N. (2003). Basic Econometrics. 4th: New York: McGraw-Hill. 
Klein, A. (2002). Audit committee, board of director characteristics, and earnings 
management. Journal of accounting and economics, 33(3), 375-400. 
Kroll, M., Walters, B. A., & Wright, P. (2008). Board vigilance, director experience, 
and corporate outcomes. Strategic Management Journal, 29(4), 363-382. 
Ongore, V. O., K’Obonyo, P. O., Ogutu, M., & Bosire, E. M. (2014). Board 
Composition and Financial Performance: Empirical Analysis of Companies 
Listed at the Nairobi Securities Exchange. International Journal of Economics 
and Financial Issues, 5(1), 23-43. 
Poon W. Heong A., Lee T., (2013). The Outcome of Politically Connected Boards on 
Modern Applied Science. 
Rezaee, Z. (2008). Corporate governance and ethics. John Wiley & Sons 
Wahba, H. (2015). The joint effect of board characteristics on financial performance: 
Empirical evidence from Egypt. Review of Accounting and Finance, 14(1), 20-
40. 
